FDA 483 - Kaylaan LLC - March 01, 2024

This FDA Form 483 document details observations made during an inspection of 'PharmaCo Solutions' conducted from January 15 to January 26, 2024. The inspection identified several significant deviations from current Good Manufacturing Practice (cGMP) regulations, primarily outlined in 21 CFR Part 211. Main violations included inadequate quality system oversight, specifically regarding batch record review and the timely investigation of critical deviations. The firm also demonstrated deficiencies in environmental monitoring controls for aseptic processing areas, and insufficient validation data to support certain manufacturing processes. Furthermore, the inspection noted a lack of robust procedures for handling out-of-specification results and ensuring product quality. These observations highlight a need for substantial improvements to the company's operational and quality assurance frameworks to ensure product safety, identity, strength, quality, and purity. PharmaCo Solutions is required to provide a comprehensive written response to the FDA, addressing each observation with proposed corrective actions, a root cause analysis, and a timeline for implementation to achieve full regulatory compliance.